Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Kowalczuk, Laura ^a,b   Touchard, Elodie ^a,b   Omri, Samy ^a,b   Jonet, Laurent ^a,b   Klein, Christophe ^a,b   Valamanes, Fatemeh ^a,b,c   Berdugo, Marianne ^a,b   Bigey, Pascal ^b,d,e,f   Massin, Pascale ^g   Jeanny, Jean Claude ^a,b   Behar Cohen, Francine ^a,b,h  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^d INSERM   (France)

^e CNRS   (France)

^f PSL RESEARCH UNIVERSITY   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

^h HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LECTIN; OCCLUDIN; PLACENTAL GROWTH FACTOR; FLUORESCEIN ISOTHIOCYANATE; PLACENTA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CELL ACTIVATION; CELL PROLIFERATION; CILIARY MUSCLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; ELECTROPORATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; GENE OVEREXPRESSION; GLIA CELL; IN VIVO STUDY; MALE; MICROANEURYSM; NONHUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; RAT; RETINA BLOOD VESSEL; SLIT LAMP; ANIMAL; CONGENITAL MALFORMATION; HUMAN; IMMUNOHISTOCHEMISTRY; MEMBRANE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; TIME;

RATTUS;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANES; MICROVESSELS; MIDDLE AGED; PREGNANCY PROTEINS; RATS; RETINAL VESSELS; TIME FACTORS;

EID: 79952379454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017462     Document Type: Article

References (57)

1. Garner A, (1993) Histopathology of diabetic retinopathy in man. Eye (Lond) 7 (Pt 2): 250-253.
2. Hammes HP, (2005) Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 37 (Suppl 1): 39-43.
3. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (22): 1480-1487.
4. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (4): 445-450.
5. th edition.
6. Sennlaub F, Valamanesh F, Vazquez-Tello A, El-Asrar AM, Checchin D, et al. (2003) Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108 (2): 198-204.
7. Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, et al. (2006) Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206 (3): 749-758.
8. Shen WY, Lai CM, Graham CE, Binz N, Lai YK, et al. (2006) Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia 49 (7): 1690-1701.
9. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, et al. (2001) Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158 (3): 1161-1172.
10. Lebherz C, Maguire AM, Auricchio A, Tang W, Aleman TS, et al. (2005) Non human Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Over-expression of Vascular Endothelial Growth Factor. Diabetes 54 (4): 1141-1149.
11. Rakoczy PE, Brankov M, Fonceca A, Zaknich T, Rae BC, et al. (2003) Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy. Diabetes 52 (3): 857-863.
12. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, et al. (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27 (4): 331-371.
13. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, et al. (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 (2): 213-216.
14. Wirostko B, Wong TY, Simó R, (2008) Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 27 (6): 608-621.
15. Parravano M, Menchini F, Virgili G, (2009) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic. Cochrane Database Syst Rev 4: CD007419.
16. Simó R, Carrasco E, Garcia-Ramirez M, Hernandez C, (2006) Angiogenic and antiangiogenic factor in proliferative diabetic retinopathy. Curr Diabetes Rev 1: 71-98.
17. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, et al. (1998) Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78: 109-116.
18. Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, et al. (2002) Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 25 (12): 2352.
19. Miyamoto N, de Kozak Y, Jeanny JC, Glotin A, Mascarelli F, et al. (2007) Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50 (2): 461-470.
20. Spirin KS, Saghizadeh M, Lewin SL, Zardi L, Kenney MC, et al. (1999) Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res 18: 490-499.
21. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG, (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci 15: 9267-9271.
22. Park JE, Chen HH, Winer J, Houck KA, Ferrara N, (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not Flk-1/KDR. J Biol Chem 269: 25646-25654.
23. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9 (7): 936-943.
24. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, et al. (1997) Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76: 517-531.
25. Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, et al. (2006) Placenta growth factor over-expression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 66 (8): 3971-3977.
26. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally active PlGF-1/VEGF heterodimers. Cancer Cell 1 (1): 99-108.
27. Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, et al. (1996) Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 271 (6): 3154-3162.
28. Yonekura H, Sakurai S, Liu X, Migita H, Wang H, et al. (1999) Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 274 (49): 35172-35178.
29. Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, et al. (1996) Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13 (3): 577-587.
30. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, et al. (2001) Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 61 (6): 2696-2703.
31. Torry RJ, Tomanek RJ, Zheng W, Miller SJ, Labarrere CA, et al. (2009) Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J Heart Lung Transplant 28 (2): 183-190.
32. Fischer C, Mazzone M, Jonckx B, Carmeliet P, (2008) Flt-1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy. Nat Rev Cancer 8 (12): 942-956.
33. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
34. Gigante B, Morlino G, Gentile MT, Persico MG, De Falco S, (2006) Plgf-/-eNos-/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. Faseb J 20 (7): 970-972.
35. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, et al. (2002) Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115: 2559-2567.
36. Feeney SA, Simpson DA, Gardiner TA, Boyle C, Jamison P, et al. (2003) Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 44 (2): 839-847.
37. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, et al. (2003) Placenta growth factor, a member of the VEGF Family, contribute to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44 (7): 3186-3193.
38. Campochiaro PA, (2006) Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13 (6): 559-562.
39. Shih SC, Ju M, Liu N, Smith LE, (2003) Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 112 (1): 50-57.
40. Bloquel C, Bejjani R, Bigey P, Bedioui F, Doat M, et al. (2006) Plasmid ET of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. Faseb J 20: 389-391.
41. Touchard E, Bloquel C, Bigey P, Kowalczuk L, Jonet L, et al. (2009) Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis. Gene Ther 16 (7): 862-873.
42. Kowalczuk L, Touchard E, Camelo S, Naud MC, Castaneda B, et al. (2009) Local ocular immunomodulation results from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Invest Ophthalmol Vis Sci 50 (4): 1761-1768.
43. Touchard E, Kowalczuk L, Bloquel C, Naud MC, Bigey P, et al. (2010) The ciliary smooth muscle electrotransfer: Basic principles and potential for sustained intraocular production of therapeutic proteins. J Gene Med. on line.
44. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, et al. (2010) Protein delivery for retinal diseases: From basic considerations to clinical applications. Prog Retin Eye Res 29 (6): 443-465.
45. Paques M, Simonutti M, Roux MJ, Picaud S, Levavasseur E, et al. (2006) High resolution fundus imaging by confocal scanning laser ophthalmoscopy in the mouse. Vision Res 46 (8-9): 1336-1345.
46. Bringmann A, Wiedemann P, (2009) Involvement of Müller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol 247 (7): 865-883.
47. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, et al. (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141 (1): 178-190.
48. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2009) Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One 3 (11): e3554.
49. Cao R, Xue Y, Hedlund EM, Zhong Z, Tritsaris K, et al. (2010) VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci U S A 107 (2): 856-861.
50. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, et al. (2003) Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 102 (4): 1515-1524.
51. Yoo SA, Yoon HJ, Kim HS, Chae CB, De Falco S, et al. (2009) Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 60 (2): 345-354.
52. Lin YL, Liang YC, Chiang BL, (2007) Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukoc Biol 82 (6): 1473-1480.
53. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (3): 463-475.
54. Roh MI, Kim HS, Song JH, Lim JB, Kwon OW, et al. (2009) Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116 (1): 80-86.
55. Regeneron Pharmaceutical (2010) VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema (news-releases February, 20 2010).
56. Dutta D, Ray S, Vivian JL, Paul S, (2008) Activation of the VEGFR1 chromatin domain: an angiogenic signal-ETS1/HIF-2alpha regulatory axis. J Biol Chem 283 (37): 25404-25413.
57. Jacob M, Unser M, (2004) Design of Steerable Filters for Feature Detection Using Canny-Like Criteria. IEEE Transactions on Pattern Analysis and Machine Intelligence 26 (8): 1007-1019.